Alpha 2.0
Login Register
» Authors » Massoud Toussi

Massoud Toussi

Explore the profile of Massoud Toussi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 23
Citations 143
Followers 0
Related Specialties
Pharmacology
Public Health
Medical Informatics
Top 10 Co-Authors
Sigal Kaplan
Hanka de Voogd
Birgit Ehlken
Wim Goettsch
Alain Venot
Lucinda Orsini
Simone Pinheiro
Sinead Langan
Monika Domahidy
David M Kern
Published In
Pharmacoepidemiol Drug Saf
BMC Med Inform Decis Mak
Curr Med Res Opin
Drug Saf
Stud Health Technol Inform
Affiliations
Soon will be listed here.
Recent Articles
1.
Effectiveness of the Additional Risk Minimisation Measures for Valproate Among Healthcare Professionals and Patients: A Cross-Sectional Survey in Six European Countries
Colas S, Nishikawa T, Dresco I, Kaplan S, Marinier K, Lachacinski A, et al.
Pharmacoepidemiol Drug Saf . 2024 Nov; 33(11):e70046. PMID: 39532540
Purpose: To assess the impact of the 2018 European additional risk minimisation measures (aRMMs) regarding the use of valproate in women of childbearing potential (WCBP) and during pregnancy. Methods: A...
2.
Impact of European Union label changes to avoid inadvertent use of medicinal products containing methotrexate for once-weekly administration: A survey amongst prescribers, pharmacists and patients on awareness, knowledge, and behaviour
Lysen T, Karimi L, Wang M, Singh S, Toussi M
Pharmacoepidemiol Drug Saf . 2023 Sep; 33(1):e5692. PMID: 37661305
Purpose: To determine the effectiveness of risk minimisation measures (RMM) to avoid inadvertent daily instead of weekly methotrexate (MTX) use, introduced by the European Medicines Agency (EMA) from 2019 onwards....
3.
Uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group
Hogervorst M, Vreman R, Heikkinen I, Bagchi I, Gutierrez-Ibarluzea I, Ryll B, et al.
Int J Technol Assess Health Care . 2023 Jun; 39(1):e40. PMID: 37325997
Objectives: Uncertainty is a fundamental component of decision making regarding access to and pricing and reimbursement of drugs. The context-specific interpretation and mitigation of uncertainty remain major challenges for decision...
4.
A drug utilization study of thiocolchicoside-containing medicinal products for systemic use in France and Italy: A cross-sectional electronic medical records database study
Druet-Cabanac A, Sophie J, Afshari R, Sahnoun R, Kouao-Kanga G, Toussi M, et al.
Pharmacoepidemiol Drug Saf . 2023 Mar; 32(10):1093-1102. PMID: 36919414
Purpose: The risk minimization measures (RMM) for systemic use of thiocolchicoside (TCC) was implemented across Europe during 2014-2016. RMM included restriction of use in age <16 years, maximum dose and...
5.
HARmonized Protocol Template to Enhance Reproducibility of Hypothesis Evaluating Real-World Evidence Studies on Treatment Effects: A Good Practices Report of a Joint ISPE/ISPOR Task Force
Wang S, Pottegard A, Crown W, Arlett P, Ashcroft D, Benchimol E, et al.
Value Health . 2022 Oct; 25(10):1663-1672. PMID: 36241338
Objectives: Ambiguity in communication of key study parameters limits the utility of real-world evidence (RWE) studies in healthcare decision-making. Clear communication about data provenance, design, analysis, and implementation is needed....
6.
HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: A good practices report of a joint ISPE/ISPOR task force
Wang S, Pottegard A, Crown W, Arlett P, Ashcroft D, Benchimol E, et al.
Pharmacoepidemiol Drug Saf . 2022 Oct; 32(1):44-55. PMID: 36215113
Problem: Ambiguity in communication of key study parameters limits the utility of real-world evidence (RWE) studies in healthcare decision-making. Clear communication about data provenance, design, analysis, and implementation is needed....
7.
A cross-sectional survey to evaluate prescribers' knowledge and understanding of safety messages following Dengvaxia® product information update
Almas M, Toussi M, Valero E, Moureau A, Marcelon L
Pharmacoepidemiol Drug Saf . 2022 May; 31(7):758-768. PMID: 35505623
Purpose: We evaluated the effectiveness of additional risk minimisation measures (aRMMs; i.e., educational materials) distributed to prescribers to ensure that only individuals with evidence of prior dengue infection (PDI, i.e.,...
8.
Overview of the European post-authorisation study register post-authorization studies performed in Europe from September 2010 to December 2018
Sultana J, Crisafulli S, Almas M, Antonazzo I, Baan E, Bartolini C, et al.
Pharmacoepidemiol Drug Saf . 2022 Jan; 31(6):689-705. PMID: 35092329
Background: The European post-authorisation study (EU PAS) register is a repository launched in 2010 by the European Medicines Agency (EMA). All EMA-requested PAS, commonly observational studies, must be recorded in...
9.
Effectiveness of risk minimization measures for valproate: a drug utilization study based on implementation of a risk minimization programme in Europe, analysis of data from the UK
Ehlken B, Nishikawa C, Kaplan S, Dresco I, Granados D, Toussi M
Curr Med Res Opin . 2021 Dec; 38(3):461-468. PMID: 34931552
Objective: Since 2014, valproate has not been recommended for use in girls and women of childbearing potential unless other treatments are ineffective or not tolerated. Risk minimization measures (RMMs) of...
10.
Safety and Persistence of Nalmefene Treatment for Alcohol Dependence. Results from Two Post-authorisation Safety Studies
Chick J, Andersohn F, Guillo S, Borchert K, Toussi M, Braun S, et al.
Alcohol Alcohol . 2021 Jul; 56(5):556-564. PMID: 34196359
Aims: Two post-authorisation studies assessed the safety and persistence of patients' use of nalmefene. Methods: The START study (EUPAS5678) was a non-interventional, multi-country, prospective, 18-month (8 follow-up visits) cohort study...